JP2017519020A - コハク酸脱水素酵素阻害剤（ＳＤＨｉ’ｓ） - Google Patents

コハク酸脱水素酵素阻害剤（ＳＤＨｉ’ｓ） Download PDF

Info

Publication number
JP2017519020A
JP2017519020A JP2016574359A JP2016574359A JP2017519020A JP 2017519020 A JP2017519020 A JP 2017519020A JP 2016574359 A JP2016574359 A JP 2016574359A JP 2016574359 A JP2016574359 A JP 2016574359A JP 2017519020 A JP2017519020 A JP 2017519020A
Authority
JP
Japan
Prior art keywords
acid
pharmaceutically acceptable
prodrug
succinate dehydrogenase
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016574359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519020A5 (enExample
Inventor
エドワード チョウチャニ
エドワード チョウチャニ
トーマス クリーグ
トーマス クリーグ
コウロッシュ サエブ−パーシー
コウロッシュ サエブ−パーシー
マイケル パトリック マーフィー
マイケル パトリック マーフィー
ロレーヌ ワーク
ロレーヌ ワーク
クリスチャン フリッザ
クリスチャン フリッザ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Cambridge Enterprise Ltd
Original Assignee
Medical Research Council
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, Cambridge Enterprise Ltd filed Critical Medical Research Council
Publication of JP2017519020A publication Critical patent/JP2017519020A/ja
Publication of JP2017519020A5 publication Critical patent/JP2017519020A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016574359A 2014-07-03 2015-07-03 コハク酸脱水素酵素阻害剤（ＳＤＨｉ’ｓ） Pending JP2017519020A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411937.4A GB201411937D0 (en) 2014-07-03 2014-07-03 Succinate dehydrogenase inhibitors (SDH's)
GB1411937.4 2014-07-03
PCT/GB2015/051949 WO2016001686A1 (en) 2014-07-03 2015-07-03 SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's)

Publications (2)

Publication Number Publication Date
JP2017519020A true JP2017519020A (ja) 2017-07-13
JP2017519020A5 JP2017519020A5 (enExample) 2018-07-19

Family

ID=51410633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574359A Pending JP2017519020A (ja) 2014-07-03 2015-07-03 コハク酸脱水素酵素阻害剤（ＳＤＨｉ’ｓ）

Country Status (10)

Country Link
US (1) US10603298B2 (enExample)
EP (1) EP3164126B1 (enExample)
JP (1) JP2017519020A (enExample)
CN (1) CN106714793B (enExample)
AU (1) AU2015282424A1 (enExample)
CA (1) CA2953709A1 (enExample)
GB (1) GB201411937D0 (enExample)
SG (1) SG11201610588UA (enExample)
WO (1) WO2016001686A1 (enExample)
ZA (1) ZA201608844B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023505365A (ja) * 2019-12-09 2023-02-08 ケンブリッジ・エンタープライズ・リミテッド 虚血性脳卒中再灌流傷害の治療または予防

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148550A1 (en) * 2017-02-10 2018-08-16 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
WO2019139831A1 (en) * 2018-01-10 2019-07-18 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate
WO2020041470A1 (en) * 2018-08-21 2020-02-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods of metabolic regulation of mitochondria for treating neural injury and neurological disorders using dsh inhibitors
CN109793760B (zh) * 2019-02-13 2022-07-19 中国人民解放军总医院 琥珀酸弧菌属在预防或治疗高原病药物中的用途
US11813239B2 (en) * 2020-02-18 2023-11-14 Wisconsin Alumni Research Foundation Compositions and methods for improving cardiac structure and/or function
GB202108594D0 (en) 2021-06-16 2021-07-28 Cambridge Entpr Ltd Treatment or prevention of ischaemia reperfusion injury
WO2025125766A1 (en) 2023-12-12 2025-06-19 Cambridge Enterprise Limited Treatment or prevention of ischaemia reperfusion injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521002A (ja) * 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク． 脳の代謝機能不全のための栄養補充剤
JP2007510734A (ja) * 2003-11-07 2007-04-26 ザ ヘンリー エム． ジャクソン ファウンデイション 低酸素誘導性遺伝子発現の活性化
US20130116337A1 (en) * 2010-06-08 2013-05-09 Richard M. LoPachin Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391662T3 (es) 2006-09-28 2012-11-28 Medical Research Council Donadores de óxido nítrico de tionitrílo de trifenilfosfonio
WO2013152193A2 (en) * 2012-04-04 2013-10-10 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
US20140128352A1 (en) * 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production
WO2014179187A1 (en) * 2013-04-29 2014-11-06 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521002A (ja) * 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク． 脳の代謝機能不全のための栄養補充剤
JP2007510734A (ja) * 2003-11-07 2007-04-26 ザ ヘンリー エム． ジャクソン ファウンデイション 低酸素誘導性遺伝子発現の活性化
US20130116337A1 (en) * 2010-06-08 2013-05-09 Richard M. LoPachin Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"OECD SIDS MALONIC ACID DIESTERS", UNEP PUBLICATIONS, JPN6019004883, 2005, ISSN: 0004110288 *
EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16, 7, 712-717, JPN6019004873, 2014, ISSN: 0004110285 *
MOLECULAR PHARMACOLOGY, 2011, 79, 5, 814-822, JPN6019004880, 2011, ISSN: 0004110287 *
PHARMACEUTICAL RESEARCH, 2011, 28, 11, 2695-2730, JPN6019004877, 2011, ISSN: 0004110286 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023505365A (ja) * 2019-12-09 2023-02-08 ケンブリッジ・エンタープライズ・リミテッド 虚血性脳卒中再灌流傷害の治療または予防

Also Published As

Publication number Publication date
WO2016001686A1 (en) 2016-01-07
US20170135977A1 (en) 2017-05-18
US10603298B2 (en) 2020-03-31
CA2953709A1 (en) 2016-01-07
ZA201608844B (en) 2019-04-24
CN106714793A (zh) 2017-05-24
CN106714793B (zh) 2020-12-01
AU2015282424A1 (en) 2017-01-12
EP3164126A1 (en) 2017-05-10
EP3164126B1 (en) 2021-02-24
GB201411937D0 (en) 2014-08-20
SG11201610588UA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
JP2017519020A (ja) コハク酸脱水素酵素阻害剤（ＳＤＨｉ’ｓ）
KR102872871B1 (ko) 모발 성장을 조절하기 위한 조성물 및 방법
EA011074B1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
JP2022510691A (ja) 線維症及び炎症の処置のための組成物
WO2020142413A1 (en) Compositions and methods for modulating hair growth
KR20090130187A (ko) 점막염 및 체중 감소의 예방 및 치료를 위한 조성물 및 방법
CN108699046A (zh) 用ezh2抑制剂治疗成神经管细胞瘤的方法
EP3863632B1 (en) Quinolylnitrone for use in the treatment and prevention of a cerebral stroke or ischaemia
US20230159461A1 (en) Compounds and methods for treating alcohol disorder
CN105431149A (zh) 神经保护多功能抗氧化剂及它们的单功能同型物
CN114096250B (zh) 红细胞生成性原卟啉症(epp)和x连锁原卟啉症(xlp)的疗法
US20230104617A1 (en) Compound for treating alzheimers disease
CN105517996B (zh) 治疗活性化合物及其使用方法
US20130225545A1 (en) Porphyrin treatment of neurodegenerative diseases
CA2862006C (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
TW201702253A (zh) 磷酸肌酸類似物前藥、其組成物及用途
EP2340020B1 (en) Manganese and cobalt complexes, their preparation and use
KR20250103971A (ko) 신규 화합물 및 이의 비알콜성 지방간염의 예방 또는 치료 용도
BR112019026080B1 (pt) Composto capaz de inibir o transportador de piruvato mitocondrial e composição farmacêutica que compreende o mesmo
HK40042691A (en) Eaat2 activators and methods of using thereof
HK40042691B (en) Eaat2 activators and methods of using thereof
BR122022021324B1 (pt) Uso de compostos inibidores do transportador de piruvato mitocondrial para tratar calvície ou alopécia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190610

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190905